MedTrace Logo

Donepezil Memory Preservation Post ECT

NCT02331771 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-07-06

No results posted yet for this study

Summary

This randomized, placebo-controlled trial will evaluate the use of donepezil compared to placebo to reduce the risk of memory impairment after electroconvulsive therapy (ECT).

Conditions

  • Memory Impairment

Interventions

DRUG

Donepezil

Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.

DRUG

Placebo

Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.

Sponsors & Collaborators

  • Porter Adventist Hospital

    lead OTHER

Principal Investigators

  • Robin Wackernah, Pharm.D. · Pharmacist

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-24
Primary Completion
2017-01-25
Completion
2017-03-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02331771 on ClinicalTrials.gov